A novel experimental pill has shown significant promise in sharply reducing artery-clogging cholesterol among individuals who remain at high risk of heart attacks, despite already being on statin medication. Researchers unveiled these findings on Wednesday, highlighting a potential breakthrough in cardiovascular care.
The pill, named enlicitide, operates by helping the body eliminate cholesterol, a mechanism currently only achievable through injected medicines. Should it gain approval from the US Food and Drug Administration, enlicitide could offer a more convenient, oral treatment option for millions of patients worldwide.
